Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ClearRing

Financiado

An innovative minimally invasive medical device used for treatment of Benign Pr...

An innovative minimally invasive medical device used for treatment of Benign Prostatic Hyperplasia symptoms Benign Prostatic Hyperplasia (BPH), or prostate enlargement, is one of the most common urological diseases among men. As the prostate enlarges with the age, it presses on and blocks the urethra, causing bothersome urinary symptoms... ver más

31/01/2022

PROARC

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

PROARC MEDICAL LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-01-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

PROARC

1.94M€ | Lider

MOLINO DE IDEAS

549.98K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 28 meses Fecha Inicio: 2019-09-16
Fecha Fin: 2022-01-31

Líder del proyecto

PROARC MEDICAL LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Descripción del proyecto Benign Prostatic Hyperplasia (BPH), or prostate enlargement, is one of the most common urological diseases among men. As the prostate enlarges with the age, it presses on and blocks the urethra, causing bothersome urinary symptoms. Over 70% of men in their 60s have symptoms of BPH 1, and 80-90% of men over 80 year old. BPH affects around 200 million men worldwide. The current methods present a significant unmet need for minimally invasive or less invasive BPH therapy as a less costly, more tolerable, and comparatively safe alternative to drugs and invasive surgery, which carry greater risk of undesirable side effects and complications. ClearRing is a revolutionary treatment of BPH symptoms, based on a pre-shaped implant and a dedicated delivery system. The ClearRing solution is the only minimally invasive system for BPH which is implantable inside the prostate with 0% chance of migration or encrustation. It puts ProArc in a unique position as a first company providing significantly improved health conditions and quality of life. Its rapid procedure enables hospitals to get patients in and out more quickly, creating a better patient experience as well as a more efficient management of medical resources. The minimally invasive procedure reduces the range and severity of side effects allowing patients to resume their normal lifestyles potentially twice as fast as the current standard operation procedure. Furthermore, it preservers sexual function. Overall objective of ProArc is to introduce a BPH treatment which is effective, affordable and with no side-effects, therefore men seek for the treatment instead of watchful waiting for the worsening. Whereas, the key objective of the project is to validate the ClearRing safety and efficacy for BPH treatment through a randomized clinical trial at 3 medical centres. This large scale clinical validation will enable ProArc to obtain the CE mark, and gradually apply for the reimbursement authorisation.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores